Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

Spreaker is getting a new look!

Preview our new listening experience personalized just for you.

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

GRACEcast

00:00

06:01

Like Download

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

8 years ago #cancer, #cancergrace, #cell, #checkpoint, #docetaxel, #gandhi, #grace, #howard, #immune, #institut, #institute, #jack, #lung, #markers, #non, #nsclc, #predictive, #small, #swedish, #west

0 Comments

This episode has no messages yet. Be the first to write a message!

Spreaker is getting a new look!

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

0 Comments

For Creators

For Listeners & Advertisers

Choose Language

Follow us